Close menu

January 5th, 2023 | 06:35 CET

It is the year 2023 and COVID is back! BioNTech, Bayer, Defence Therapeutics, Morphosys - Which stocks stand up to the virus from China?

  • Biotechnology
  • Covid19
  • Cancer
Photo credits:

The next COVID wave is raging in China. The situation is no less dramatic today than in 2019 because until now, only vaccines produced in the country may be administered to locals in China. Before Christmas, however, the German government obtained permission to have Germans in China vaccinated with the active ingredient from BioNTech and immediately had the first doses flown out to Beijing. Yesterday, the EU discussed a joint reaction to the current conditions in China. German medical officials are calling for mandatory Europe-wide testing of all people entering the country and are warning of a new, dangerous virus mutation due to the large numbers of infections. Investors are therefore taking the vaccine experts back into focus.

time to read: 4 minutes | Author: André Will-Laudien

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    BioNTech and Bayer - Blockbusters in the pipeline

    The EU has offered its help to China to contain the pandemic. The EU Commissioner for Health, Stella Kyriakides, has made a corresponding offer to the leadership in Beijing, but the Middle Kingdom has yet to respond. The EU department did not provide information on the number of vaccines offered or the manufacturers. Nevertheless, BioNTech will likely be back at the top of investors' minds regarding COVID-19. With the mRNA vaccine "Comirnaty", the Mainz-based company has generated around EUR 20 billion in net cash flow in 2021/22 and can now focus on the next blockbuster with full pockets. A clinical trial for a novel malaria vaccine was started shortly before Christmas. BioNTech's market capitalization of EUR 34 billion is 60% cash backed, with a promising pipeline.

    Bayer is one of Germany's flagship cancer research companies. The pharma division is specifically committed to the development of precision oncology, as it benefits from major advances in the field of molecular diagnostics. Next-generation sequencing, for example, enables the detection of genome alterations that promote tumor growth and provides important information about how likely a patient is to respond to treatment. For Bayer, the pharmaceuticals and health sectors continue to be the earnings pearl in the Group. In the last nine months, it earned EUR 5.6 billion (EBITDA).

    Full-year figures will be published on February 28. Bayer shares ended the 2022 stock market year with a maintained price of around EUR 48 and are now heading towards EUR 50 at the start of the year. With an estimated 2023 P/E ratio of 7.2 and a dividend yield of 4.5%, the stock still has plenty of room to run.

    Defence Therapeutics - With ACCUM(TM) technology through the nose against lung cancer

    The Canadian biotech specialist Defence Therapeutics (DTC) has developed a patented technology with its ACCUM(TM) platform, which gives great hope in current cancer research because the combination of mRNA technology with modern methods of delivery to affected cells is a real advance within recent research. Defence Therapeutics has now completed a preclinical study using the intranasal formulation of AccuTOX in animals with existing lung cancer. The study showed that administration of AccuTOX as a combination therapy with the immune checkpoint inhibitor anti-PD1 dramatically reduced the number of lung nodules compared to untreated or anti-PD1 treated control animals. This 50% reduction in cancer nodules in animals with existing lung tumors was achieved with a treatment schedule of only six doses administered over two weeks with the AccuTOX anti-PD1 combination.

    "We are very excited about the versatile use of AccuTOX as a cancer therapy. Not only has the compound shown great potential in the treatment of solid tumors, but we now have data showing that it can be further adapted and administered via the intranasal route to treat lungs with metastatic tumors, offering new hope for lung cancer patients," said CEO Sebastien Plouffe.

    Defence Therapeutics is also showing early success with its ACCUM(TM) technology in solid tumors. It will be interesting to see what other pipeline the Company can come up with in 2023. The share price has risen considerably in the last three months, but the market capitalization is still low at EUR 69 million. Technically, however, a significant bottoming took place in October, and the share price is now striving further upwards. Defence Therapeutics has blockbuster potential!

    Morphosys - Despite new downgrades, the share price has turned

    Morphosys presented a real disappointment in November. The Alzheimer's hopeful Gantenerumab could not meet expectations even on the second attempt. After the great trial success of Biogen with the product Lecanemab, the shock of the investors, in this case, was striking. The share collapsed by over 40% within 48 hours, from EUR 21 to EUR 13. However, according to statements made by CFO Sung Lee on the fringes of the Equity Forum in Frankfurt, Morphosys currently still has liquid assets of around EUR 1 billion. The current market capitalization is only EUR 463 million. In December, the stock also hit a 20-year low of EUR 11.85.

    For the Munich-based company, everything now revolves around the two cancer drugs, Monjuvi and Pelabresib. And here, sales are also rather bumpy, with profits only mentioned from 2025 onwards. The mood is correspondingly poor and further analysts lowered their expectations. Most recently, there were three downgrades from Deutsche Bank, Goldman Sachs and JPMorgan, and the short ratio is still relatively high. None of this is an incentive to buy - but the mood for the share is so bad that, technically, it can only go up. Yesterday, the value rose again above EUR 14.20 with high turnover. Traders stay put as momentum increases and bet on a 100% turnaround in 2023! In any case, install a safety stop at EUR 11.80.

    For most biotech stocks, the past year was no bed of roses. Accordingly, the recovery potentials are now good to assess. Whether COVID is a trigger again has yet to be discovered. What is certain is that the focus will continue to be on the century-long task of combating cancer. Bayer, BioNTech, Defence Therapeutics and Morphosys have significant research pipelines in this area and have recently made some progress.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author

    Related comments:

    Commented by Juliane Zielonka on May 23rd, 2024 | 08:45 CEST

    Defence Therapeutics, Super Micro Computer, Evotec: Fresh patents, revenue explosion, and cyberattacks - These companies overcome all hurdles

    • Biotechnology
    • Pharma
    • AI

    Medicine and research go hand in hand. The Canadian biotech company Defence Therapeutics is expanding its patent protection for its platform technology in order to further advance the development of drugs, vaccines, and active ingredients. Data collection and analysis require intelligent solutions such as those from Super Micro Computer. With an incredible 200% increase in revenue, the US company from Silicon Valley is surfing the digital wave of success. Will they continue to rise? Meanwhile, Evotec is grappling with the darker side of digitalization. Due to a cyberattack, the life sciences company is withdrawing from an otherwise lucrative segment. We provide the details.


    Commented by Stefan Feulner on May 22nd, 2024 | 07:00 CEST

    BioNTech, Cardiol Therapeutics, Morphosys - On the verge of a breakout

    • Biotechnology
    • Pharma

    Compared to the broader indices, DAX and Dow Jones, which have already reached new all-time highs, the Nasdaq Biotech Index is currently lagging. The sector index is still around 23% below its peak from August 2021. Nevertheless, the sector is on the move. In addition to takeovers, which have increased dramatically in 2024, many companies have important study results in the pipeline that could kick-start a rally.


    Commented by Fabian Lorenz on May 16th, 2024 | 08:00 CEST

    Share price shock at Siemens Energy! What are BioNTech and Cardiol Therapeutics doing?

    • Biotechnology
    • Pharma
    • renewableenergies

    The Siemens Energy share has been one of the surprises of recent months. It has more than doubled since the beginning of the year. Is a crash now imminent? Yes, if you believe Bernstein. Their analysts are shocking us with a horror price target. The Cardiol Therapeutics share performed even better than Siemens Energy in 2024. Despite the 150% rally, analysts see upside potential for the cardiovascular disease specialist. Things will get really exciting at the beginning of June when new study results are due. BioNTech, on the other hand, is currently failing to convince analysts. Reactions to the latest quarterly figures were modest.